DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of two abstracts on its soluble CD83 (sCD83) protein program at the 2009 Annual Scientific Conference of the Canadian Society of Transplantation, held March 5 - 8 in Banff, Alberta. The presentations, to be made on March 7 by Argos’ collaborating scientists from the University of Western Ontario, detail positive preclinical data for sCD83 in organ transplantation models, as well its ability to induce and maintain immune tolerance via its generation of tolerogenic dendritic cells (DC) and its direct suppressive effects on T cells and B cells.
